Publications

Detailed Information

Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer

DC Field Value Language
dc.contributor.authorHan, Wonshik-
dc.contributor.authorHan, Mi-Ryung-
dc.contributor.authorKang, Jason Jongho-
dc.contributor.authorBae, Ji-Yeon-
dc.contributor.authorLee, Ji Hyun-
dc.contributor.authorBae, Young Ju-
dc.contributor.authorLee, Jeong Eon-
dc.contributor.authorShin, Hyuk-Jae-
dc.contributor.authorHwang, Ki-Tae-
dc.contributor.authorHwang, Sung-Eun-
dc.contributor.authorKim, Sung-Won-
dc.contributor.authorNoh, Dong-Young-
dc.date.accessioned2009-11-09T22:55:28Z-
dc.date.available2009-11-09T22:55:28Z-
dc.date.issued2006-04-13-
dc.identifier.citationBMC Cancer. 2006 Apr 12;6:92en
dc.identifier.issn1471-2407 (Electronic)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16608533-
dc.identifier.urihttps://hdl.handle.net/10371/11787-
dc.description.abstractBACKGROUND: A considerable proportion of estrogen receptor (ER)-positive breast cancer recurs despite tamoxifen treatment, which is a serious problem commonly encountered in clinical practice. We tried to find novel prognostic markers in this subtype of breast cancer. METHODS: We performed array comparative genomic hybridization (CGH) with 1,440 human bacterial artificial chromosome (BAC) clones to assess copy number changes in 28 fresh-frozen ER-positive breast cancer tissues. All of the patients included had received at least 1 year of tamoxifen treatment. Nine patients had distant recurrence within 5 years (Recurrence group) of diagnosis and 19 patients were alive without disease at least 5 years after diagnosis (Non-recurrence group). RESULTS: Potential prognostic variables were comparable between the two groups. In an unsupervised clustering analysis, samples from each group were well separated. The most common regions of gain in all samples were 1q32.1, 17q23.3, 8q24.11, 17q12-q21.1, and 8p11.21, and the most common regions of loss were 6q14.1-q16.3, 11q21-q24.3, and 13q13.2-q14.3, as called by CGH-Explorer software. The average frequency of copy number changes was similar between the two groups. The most significant chromosomal alterations found more often in the Recurrence group using two different statistical methods were loss of 11p15.5-p15.4, 1p36.33, 11q13.1, and 11p11.2 (adjusted p values < 0.001). In subgroup analysis according to lymph node status, loss of 11p15 and 1p36 were found more often in Recurrence group with borderline significance within the lymph node positive patients (adjusted p = 0.052). CONCLUSION: Our array CGH analysis with BAC clones could detect various genomic alterations in ER-positive breast cancers, and Recurrence group samples showed a significantly different pattern of DNA copy number changes than did Non-recurrence group samples.en
dc.language.isoenen
dc.publisherBioMed Centralen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Agents, Hormonal/*therapeutic useen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/administration &en
dc.subjectdosage/therapeutic useen
dc.subjectBreast Neoplasms/chemistry/drug therapy/*genetics/radiotherapy/surgeryen
dc.subjectCarcinoma, Ductal, Breast/chemistry/drugen
dc.subjecttherapy/*genetics/radiotherapy/secondary/surgeryen
dc.subjectChemotherapy, Adjuvanten
dc.subjectChromosomes, Artificial, Bacterialen
dc.subjectCluster Analysisen
dc.subjectCombined Modality Therapyen
dc.subjectCyclophosphamide/administration & dosageen
dc.subjectDNA, Neoplasm/*geneticsen
dc.subjectDisease-Free Survivalen
dc.subjectEstrogen Receptor Modulators/*therapeutic useen
dc.subjectFemaleen
dc.subjectFluorouracil/administration & dosageen
dc.subjectHumansen
dc.subjectLife Tablesen
dc.subjectMastectomyen
dc.subjectMethotrexate/administration & dosageen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Metastasisen
dc.subjectNeoplasm Proteins/analysisen
dc.subjectNeoplasms, Hormone-Dependent/chemistry/drugen
dc.subjecttherapy/*genetics/radiotherapy/surgeryen
dc.subjectOligonucleotide Array Sequence Analysisen
dc.subjectPrognosisen
dc.subjectRadiotherapy, Adjuvanten
dc.subjectReceptors, Estrogen/analysisen
dc.subjectTamoxifen/*therapeutic useen
dc.subjectEstrogens-
dc.subjectNucleic Acid Hybridization-
dc.titleGenomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast canceren
dc.typeArticleen
dc.contributor.AlternativeAuthor한원식-
dc.contributor.AlternativeAuthor한미령-
dc.contributor.AlternativeAuthor배지연-
dc.contributor.AlternativeAuthor이지현-
dc.contributor.AlternativeAuthor배영주-
dc.contributor.AlternativeAuthor이정언-
dc.contributor.AlternativeAuthor신혁재-
dc.contributor.AlternativeAuthor황기태-
dc.contributor.AlternativeAuthor황성은-
dc.contributor.AlternativeAuthor김성원-
dc.contributor.AlternativeAuthor노동영-
dc.identifier.doi10.1186/1471-2407-6-92-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share